Journal: Molecular therapy. Methods & clinical development

Article Title: Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus.

doi: 10.1016/j.omtm.2022.05.006

Figure Lengend Snippet: Figure 3. Immunophenotyping of 1D3-CD19CAR- GFP (blue, circle), FMC63-CD19CAR-GFP (red, square), or control (GFP only, green, triangle) trans- duced T cells in peripheral blood of treated mice Values shown are the percentage of total CD3+, CD90.2+

Article Snippet: In order to verify the ability for both the 1D3-and FMC63-CD19CAR to target the mouse CD19 antigen, the A20 cells were incubated with 10, 1, 0.1, 0.001, or 0 mg/mL of either the 1D3CD19-blocking antibody (152402, BioLegend) or the FMC63-CD19- Molecular Th blocking antibody (NBP2-52716, Novus Biologicals).

Techniques: Control

Journal: Frontiers in Immunology

Article Title: Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

doi: 10.3389/fimmu.2022.1058126

Figure Lengend Snippet: Univariate analysis of ICANS.

Article Snippet: Cells were stained with the CD19 CAR FMC63 Idiotype antibody-APC (Miltenyi Biotec, Bergisch-Gladbach, Germany) following the manufacturer’s instruction.

Techniques: Biomarker Discovery

Journal: STAR Protocols

Article Title: Inducing T cell dysfunction by chronic stimulation of CAR-engineered T cells targeting cancer cells in suspension cultures

doi: 10.1016/j.xpro.2022.101954

Figure Lengend Snippet:

Article Snippet: PE-labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 (Y45) , Acro Biosystems , Cat# FM3-HPY53; RRID: AB_2921284.

Techniques: Recombinant, Reverse Transcription, Software, Pore Size, Flow Cytometry, Transfection